Skip to main content
. 2023 Oct 17;101(16):700–713. doi: 10.1212/WNL.0000000000207622

Table 3.

Studies Registered With ClinicalTrials.gov as Treatment Approaches of PML-IRIS and Recently Published (2019–2023) Case Studies

graphic file with name WNL-2023-000430t3.jpg

Study phase Identifier Principal investigator/study chair/responsible party Drug Rational Primary outcome No. of participants Status Result Publication
Phase IV NCT01211665 Biogen Inc., the United States Methylprednisolone prednisolone To prevent and/or limit the deleterious immune responses in natalizumab-associated PML-IRIS Time course change in functional status based on Karnofsky Performance Status Index 3 Terminated because of lack of enrollment (2012) N/A N/A
Retrospective NCT03969550 Fondation Ophtalmologique Adolphe de Rothschild, France Maraviroc (CCR5 antagonist) as part of cART To prevent and/or limit the deleterious immune responses in AIDS-related PML Overall survival (OS), time frame: 8 y 34 Completed (2015) No clinically relevant benefit e72
Drug No. of treated patients Reported outcome of PML Publication
Improvement/stabilization Death
Steroids 4 4 0 e73-e76
Maraviroc 2 2 0 e77,e78

Abbreviations: IRIS = immune reconstitution inflammatory syndrome; PML = progressive multifocal leukoencephalopathy.